Search

Your search keyword '"Nicolas-Virelizier E"' showing total 146 results
Start Over Author "Nicolas-Virelizier E"
146 results on '"Nicolas-Virelizier E"'

1. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

Author

Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., and Blay, J.-Y.

Published
2021
Full Text
View/download PDF

3. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

Author

Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Cassoux, N., Touitou, V., Le Garff-Tavernier, M., Savignoni, A., Turbiez, I., Soumelis, V., Houillier, C., and Soussain, C.

Published
2019
Full Text
View/download PDF

4. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

Author

Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., Willems, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., Haioun, C., Damaj, G., Gaulard, P., Fornecker, L., Ghesquières, H., Tournilhac, O., da Silva, M. Gomes, Bouabdallah, R., Salles, G., and Bachy, E.

Published
2018
Full Text
View/download PDF

7. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

Author

Bento, L, Boumendil, A, Finel, H, Le Gouill, S, Amorim, S, Monjanel, H, Bouabdallah, R, Bay, J O, Nicolas-Virelizier, E, McQuaker, G, Rossi, G, Johnson, R, Huynh, A, Ceballos, P, Rambaldi, A, Bachy, E, Malladi, R, Orchard, K, Pohlreich, D, Tilly, H, Bonifazi, F, Poiré, X, Guilhot, F, Haenel, A, Crawley, C, Metzner, B, Gribben, J, Russell, N H, Damaj, G, Thomson, K, Dreger, P, and Montoto, S

Published
2017
Full Text
View/download PDF

9. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

Author

Robinson, S P, Boumendil, A, Finel, H, Blaise, D, Poiré, X, Nicolas-Virelizier, E, Or, R, Malladi, R, Corby, A, Fornecker, L, Caballero, D, Pohlreich, D, Nagler, A, Thieblemont, C, Finke, J, Bachy, E, Vincent, L, Schroyens, W, Schouten, H, and Dreger, P

Published
2016
Full Text
View/download PDF

11. Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’

Author

Fossard, G., primary, Broussais, F., additional, Coelho, I., additional, Bailly, S., additional, Nicolas-Virelizier, E., additional, Toussaint, E., additional, Lancesseur, C., additional, Le Bras, F., additional, Willems, E., additional, Tchernonog, E., additional, Chalopin, T., additional, Delarue, R., additional, Gressin, R., additional, Chauchet, A., additional, Gyan, E., additional, Cartron, G., additional, Bonnet, C., additional, Haioun, C., additional, Damaj, G., additional, Gaulard, P., additional, Fornecker, L., additional, Ghesquières, H., additional, Tournilhac, O., additional, Gomesda Silva, M., additional, Bouabdallah, R., additional, Salles, G., additional, and Bachy, E., additional

Published
2021
Full Text
View/download PDF

12. CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY

Author

Bohers, E, primary, Delfau‐Larue, M, additional, Vercellino, L, additional, Cottereau, A, additional, Viennot, M, additional, Viailly, P, additional, Salles, G, additional, Tilly, H, additional, Damaj, G, additional, Haioun, C, additional, Ribrag, V, additional, Morschhauser, F, additional, Casasnovas, R, additional, Nicolas‐Virelizier, E, additional, Feugier, P, additional, Bouabdallah, R, additional, Cartron, G, additional, Renaud, L, additional, Chartier, L, additional, Portugues, C, additional, Meignan, M, additional, Jardin, F, additional, and Thieblemont, C, additional

Published
2021
Full Text
View/download PDF

13. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Author

Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A, Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL., Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicola, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-Françoi, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A, Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL., Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Lymphoma and Myeloma [Houston, TX, USA], The University of Texas M.D. Anderson Cancer Center [Houston], Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d’Hématologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Unité des hémopathies lymphoïdes [CHU Henri Mondor], CHU Henri Mondor, Service d’Onco-Hématologie [La Roche sur Yon], Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'hématologie [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service d'onco-hématologie [AP-HP Hôpital Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'Hématologie Clinique [Hôpital Hôtel Dieu, Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Hôtel Dieu, Service Hématologie [CH Métropole Savoie, Chambery], Centre Hospitalier Métropole Savoie [Chambéry], Département d'Hématologie [CHU de Montpellier], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Département d'Hématologie [CH Lyon-Sud], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), RELEVANCE Trial Investigators : Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL., Bernardo, Elizabeth, CHU Henri Mondor [Créteil], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier Départemental Vendée, Service d'Hématologie [IUCT Toulouse], Université Fédérale Toulouse Midi-Pyrénées-Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
Adult, Male, medicine.medical_specialty, Neutropenia, Intention to Treat Analysi, Follicular lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, Skin Diseases, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Maintenance therapy, immune system diseases, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival rate, Lenalidomide, Lymphoma, Follicular, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, business.industry, Skin Disease, General Medicine, Middle Aged, medicine.disease, 3. Good health, Intention to Treat Analysis, Thalidomide, Survival Rate, Regimen, 030220 oncology & carcinogenesis, Rituximab, Female, business, Febrile neutropenia, 030215 immunology, medicine.drug, Human
Abstract

International audience; BACKGROUND:Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.METHODS:We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival.RESULTS:A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P=0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximab-chemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%).CONCLUSIONS:Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups. (Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701 , and EudraCT number, 2011-002792-42 .).

Published
2018
Full Text
View/download PDF

14. Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Author

Sesques, P, Ferrant, E, Safar, V, Wallet, F, Tordo, J, Dhomps, A, Karlin, L, Brisou, G, Vercasson, M, Hospital-Gustem, C, Schwiertz, V, Ranchon, F, Rioufol, C, Choquet, M, Sujobert, P, Ghergus, D, Bouafia, F, Golfier, C, Lequeu, H, Lazareth, A, Novelli, S, Devic, P, Glehen, AT, Viel, S, Venet, F, Mialou, V, Hequet, O, Chauchet, A, Arkam, Y, Nicolas-Virelizier, E, Peyrade, F, Cavalieri, D, Ader, F, Ghesquieres, H, Salles, G, and Bachy, E

Abstract

Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of use, efficacy and safety for axi-cel and tisa-cel. Data from 70 patients who underwent apheresis for commercial CAR T cells between January 2018 and November 2019 in our institution were retrospectively collected. Sixty-one patients were infused. The median age at infusion was 59 years old (range 27-75 years). The median number of prior therapies was 3 (range, 2-6). The overall response rates (ORRs) at 1 month and 3 months were 63% and 45%, respectively, with 48% and 39% achieving a complete response (CR), respectively. After a median follow-up after infusion of 5.7 months, the median progression-free survival (PFS) was 3.0 months (95% CI, 2.8-8.8 months), and the median overall survival (OS) was 11.8 months (95% CI, 6.0-12.6 months). In multivariate analysis, factors associated with poor PFS were the number of previous lines of treatment before CAR T cells (>= 4) (P= .010) and a C reactive protein (CRP) value >30 mg/L at the time of lymphodepletion (P 30 mg/L (P= .009). Cytokine release syndrome (CRS) of any grade occurred in 85% of patients, including 8% of patients with CRS of grade 3 or higher. Immune cell-associated neurotoxicity syndrome (ICANS) of any grade occurred in 28% of patients, including 10% of patients with ICANS of grade 3 or higher. Regarding efficacy and safety, no significant difference was found between axi-cel and tisa-cel. This analysis describes one of the largest real-life cohorts of patients treated with axi-cel and tisa-cel for R/R aggressive B cell lymphoma in Europe.

Published
2020

15. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis

Author

Kastritis, E. Leleu, X. Arnulf, B. Zamagni, E. Cibeira, M.T. Kwok, F. Mollee, P. Hajek, R. Moreau, P. Jaccard, A. Schonland, S.O. Filshie, R. Nicolas-Virelizier, E. Augustson, B. Mateos, M.-V. Wechalekar, A. Hachulla, E. Milani, P. Dimopoulos, M.A. Fermand, J.-P. Foli, A. Gavriatopoulou, M. Klersy, C. Palumbo, A. Sonneveld, P. Erik Johnsen, H. Merlini, G. Palladini, G.

Abstract

PURPOSE Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex). METHODS This was a phase III, multicenter, randomized, open-label trial. Patients were stratified according to cardiac stage. Patients with advanced cardiac stage (stage IIIb) amyloidosis were not eligible. The primary end point was hematologic response rate at 3 months. This trial is registered with ClinicalTrials.gov identifier NCT01277016. RESULTS A total of 109 patients, 53 in the BMDex and 56 in the MDex group, received $1 dose of therapy (from January 2011 to February 2016). Hematologic response rate at 3 months was higher in the BMDex arm (79% v 52%; P 5 .002). Higher rates of very good partial or complete response rates (64% v 39%; hazard ratio [HR], 2.47; 95% CI, 1.30 to 4.71) and improved overall survival, with a 2-fold decrease in mortality rate (HR, 0.50; 95% CI, 0.27 to 0.90), were observed in the BMDex arm. Grade 3 and 4 adverse events (the most common being cytopenia, peripheral neuropathy, and heart failure) were more common in the BMDex arm, occurring in 20% versus 10% of cycles performed. CONCLUSION BMDex improved hematologic response rate and overall survival. To our knowledge, this is the first time a controlled study has demonstrated a survival advantage in AL amyloidosis. BMDex should be considered a new standard of care for AL amyloidosis. © 2020 by American Society of Clinical Oncology.

Published
2020

16. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma

Author

Manson, G., primary, Brice, P., additional, Herbaux, C., additional, Silva, M. G., additional, Bouabdallah, K., additional, Deau, B., additional, Bouteloup, J., additional, Schiano, J. M., additional, Nicolas-Virelizier, E., additional, Maerevoet, M., additional, Ghesquieres, H., additional, Stamatoullas, A., additional, Antier, C., additional, Carlo-Stella, C., additional, de Charette, M., additional, Poizeau, F., additional, Dercle, L., additional, and Houot, Roch, additional

Published
2020
Full Text
View/download PDF

17. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

Author

Van Gelder, M, De Wreede, L, Bornhauser, M, Niederwieser, D, Karas, M, Anderson, N, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J, Yakoub-Agha, I, Russell, N, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispizua, A, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, Van Biezen, A, Henseler, A, Schonland, S, Kroger, N, Schetelig, J, Ehninger, G, Jindra, P, Sengeloev, H, Ispizua, A, Arnold, R, Veelken, J, Mufti, G, Milpied, N, Benedetto, B, Schaap, M, Leblond, V, Nikolousis, M, Hallek, M, Passweg, J, Ljungman, P, Masszi, T, Stelljes, M, Browne, P, Glass, B, Espiga, C, Bourhis, J, Roussy, G, Gribben, J, Foa, R, Sierra, J, Mayer, J, Thomson, K, Meijer, E, Blau, W, Holler, E, Bacigalupo, A, Guilhot, F, Carlson, K, Zachee, P, Ifrah, N, Marin, J, Socie, G, Mcquaker, G, Cortelezzi, A, Lenhoff, S, Tischer, J, Irrera, G, Fanin, R, Beguin, Y, Nagler, A, Mackinnon, S, Itala-Remes, M, Deconinck, E, Wulf, G, Corradini, P, Gilleece, M, Wing, B, Peniket, A, Ganser, A, Stuhler, G, Faber, E, Komarnicki, M, Kanz, L, Brune, M, Lamy, T, Sanz, M, Kyrcz-Krzemien, S, Orchard, K, Hunter, A, Sandstedt, A, Fegueux, N, Bandini, G, Robinson, S, Craddock, C, Crawley, C, Griskevicius, L, Bloor, A, Reman, O, Hilgendorf, I, Cannell, P, Ciceri, F, Kalhs, P, Sica, S, Greinix, H, Scime, R, Selleslag, D, Kruger, W, Huynh, A, Einsele, H, Bittenbring, J, Olivieri, A, Hermine, O, Gedde-Dahl, T, Zsiros, J, Guyotat, D, Cordonnier, C, Campos, A, Casini, M, Martinelli, G, Muller, L, Van Imhoff, G, Neubauer, A, Lioure, B, Hamladji, R, Noens, L, Theobald, M, Salvi, F, Ram, R, Poire, X, Or, R, Chalandon, Y, Solano, C, Wilson, K, Santasusana, J, Karakasis, D, Schafer-Eckart, K, Wahlin, A, Mohty, M, Velardi, A, Bron, D, Alegre, A, Cairoli, R, Marotta, G, Lange, A, Narni, F, Fauser, A, Rambaldi, A, Guillerm, G, Heras, I, Snowden, J, Wiktor-Jedrzejczak, W, Schanz, U, Cahn, J, Abecasis, M, Kobbe, G, Salim, R, Junghanss, C, Segel, E, Clement, L, Zak, P, Metzner, B, Espigado, I, Tilly, H, Schroyens, W, Favre, C, Russo, D, Gastl, G, Bay, J, Alessandrino, E, Majolino, I, Bosi, A, Zuckerman, T, Aljurf, M, Thomson, J, Pioltelli, P, Anagnostopoulos, A, Schouten, H, Tholouli, E, Gurman, G, Vural, F, Zver, S, Muniz, S, Afanasyev, B, Pohlreich, D, Hellmann, A, Rosler, W, Martin, S, Apperley, J, Finnegan, D, Renaud, M, Nemet, D, Culligan, D, Castagna, L, Cascavilla, N, Koh, M, Chacon, M, Ozdogu, H, Spencer, A, Llamas, C, Grasso, M, Lopez, S, Benedetti, F, Deeren, D, De Revel, T, Musso, M, Halaburda, K, Sureda, A, Angelucci, E, Diez-Martin, J, Hunter, H, Koc, Y, Bordessoule, D, Fouillard, L, Di Bartolomeo, P, Mazza, P, Novitzky, N, Peschel, C, Lopez, J, Cascon, M, Romeril, K, Schots, R, Brussel, H, Koistinen, P, Arcese, W, Aktan, M, Rodeghiero, F, Butler, A, Pizzuti, M, Melpignano, A, Carella, A, Valcarcel, D, De Toledo Codina, J, Galieni, P, Bader, P, Hahn, Cavanna, L, Sucak, G, Broom, A, Garcia, P, Nicolas-Virelizier, E, Rizzoli, V, Witz, F, Collin, M, Ringhoffer, M, Kansu, E, Martin, H, Moraleda, J, Pranger, D, Greil, R, Bazarbachi, A, Ozturk, M, Fagioli, F, Jantunen, E, Yeshurun, M, Altuntas, F, Bassan, R, Rohrlich, P, Jimenez, S, Glaisner, S, Vinante, O, Clausen, J, Lopez-Jimenez, J, Theunissen, K, Specchia, G, Pavone, V, Krauter, J, Edwards, D, Rifon, J, Everaus, H, Da Prada, G, Wattad, M, Milone, G, Walewski, J, Thieblemont, C, Nasa, G, Duchosal, M, Ferrara, F, Devidas, A, Delmer, A, Degos, L, Van Gelder M., De Wreede L. C., Bornhauser M., Niederwieser D., Karas M., Anderson N. S., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen J. J., Yakoub-Agha I., Russell N. H., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., Van Biezen A., Henseler A., Schonland S., Kroger N., Schetelig J., Ehninger G., Jindra P., Sengeloev H., Russell N., Ispizua A. U., Arnold R., Veelken J. H., Mufti G., Milpied N., Benedetto B., Schaap M., Leblond V., Nikolousis M., Hallek M., Passweg J., Ljungman P., Masszi T., Stelljes M., Browne P., Glass B., Espiga C. R., Bourhis J. H., Roussy G., Gribben J., Foa R., Sierra J., Mayer J., Thomson K., Meijer E., Blau W., Holler E., Bacigalupo A., Guilhot F., Carlson K., Zachee P., Ifrah N., Marin J. R. C., Socie G., McQuaker G., Cortelezzi A., Lenhoff S., Tischer J., Irrera G., Fanin R., Beguin Y., Nagler A., Mackinnon S., Itala-Remes M., Deconinck E., Wulf G., Corradini P., Gilleece M., Wing B., Peniket A., Ganser A., Stuhler G., Faber E., Komarnicki M., Kanz L., Brune M., Lamy T., Sanz M., Kyrcz-Krzemien S., Orchard K., Hunter A., Sandstedt A., Fegueux N., Bandini G., Robinson S., Craddock C., Crawley C., Griskevicius L., Bloor A., Reman O., Hilgendorf I., Cannell P., Ciceri F., Kalhs P., Sica S., Greinix H., Scime R., Selleslag D., Kruger W., Huynh A., Einsele H., Bittenbring J., Olivieri A., Hermine O., Gedde-Dahl T., Zsiros J., Guyotat D., Cordonnier C., Campos A., Casini M., Martinelli G., Muller L. P., Van Imhoff G., Neubauer A., Lioure B., Hamladji R. -M., Noens L., Theobald M., Salvi F., Ram R., Poire X., Or R., Chalandon Y., Solano C., Wilson K., Santasusana J. M. R., Karakasis D., Schafer-Eckart K., Wahlin A., Mohty M., Velardi A., Bron D., Alegre A., Cairoli R., Marotta G., Lange A., Narni F., Fauser A., Rambaldi A., Guillerm G., Heras I., Snowden J., Wiktor-Jedrzejczak W., Schanz U., Cahn J. Y., Abecasis M., Kobbe G., Salim R., Junghanss C., Segel E. K., Clement L., Zak P., Metzner B., Espigado I., Tilly H., Schroyens W., Favre C., Russo D., Gastl G., Bay J. -O., Alessandrino E. P., Majolino I., Bosi A., Zuckerman T., Aljurf M., Thomson J., Pioltelli P., Anagnostopoulos A., Schouten H., Tholouli E., Gurman G., Vural F., Zver S., Muniz S. G., Afanasyev B., Pohlreich D., Hellmann A., Rosler W., Martin S., Apperley J., Finnegan D., Renaud M., Nemet D., Culligan D., Castagna L., Cascavilla N., Koh M., Chacon M. J., Ozdogu H., Spencer A., Llamas C. V., Grasso M., Lopez S. G., Benedetti F., Deeren D., De Revel T., Musso M., Halaburda K., Sureda A., Angelucci E., Diez-Martin J. L., Hunter H., Koc Y., Bordessoule D., Fouillard L., Di Bartolomeo P., Mazza P., Novitzky N., Peschel C., Lopez J. L. B., Cascon M. J. P., Romeril K. R., Schots R., Brussel H., Koistinen P., Arcese W., Aktan M., Rodeghiero F., Butler A., Pizzuti M., Melpignano A., Carella A. M., Valcarcel D., De Toledo Codina J. S., Galieni P., Bader P., Cavanna L., Sucak G., Broom A. J. M., Garcia P. G., Nicolas-Virelizier E., Rizzoli V., Witz F., Collin M., Ringhoffer M., Kansu E., Martin H., Moraleda J., Pranger D., Greil R., Bazarbachi A., Ozturk M., Fagioli F., Jantunen E., Yeshurun M., Altuntas F., Bassan R., Rohrlich P. -S., Jimenez S., Glaisner S., Vinante O., Clausen J., Lopez-Jimenez J., Theunissen K., Specchia G., Pavone V., Krauter J., Edwards D., Rifon J., Everaus H., Da Prada G. A., Wattad M., Milone G., Walewski J., Thieblemont C., Nasa G. L., Duchosal M., Ferrara F., Devidas A., Delmer A., Degos L., Van Gelder, M, De Wreede, L, Bornhauser, M, Niederwieser, D, Karas, M, Anderson, N, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J, Yakoub-Agha, I, Russell, N, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispizua, A, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, Van Biezen, A, Henseler, A, Schonland, S, Kroger, N, Schetelig, J, Ehninger, G, Jindra, P, Sengeloev, H, Ispizua, A, Arnold, R, Veelken, J, Mufti, G, Milpied, N, Benedetto, B, Schaap, M, Leblond, V, Nikolousis, M, Hallek, M, Passweg, J, Ljungman, P, Masszi, T, Stelljes, M, Browne, P, Glass, B, Espiga, C, Bourhis, J, Roussy, G, Gribben, J, Foa, R, Sierra, J, Mayer, J, Thomson, K, Meijer, E, Blau, W, Holler, E, Bacigalupo, A, Guilhot, F, Carlson, K, Zachee, P, Ifrah, N, Marin, J, Socie, G, Mcquaker, G, Cortelezzi, A, Lenhoff, S, Tischer, J, Irrera, G, Fanin, R, Beguin, Y, Nagler, A, Mackinnon, S, Itala-Remes, M, Deconinck, E, Wulf, G, Corradini, P, Gilleece, M, Wing, B, Peniket, A, Ganser, A, Stuhler, G, Faber, E, Komarnicki, M, Kanz, L, Brune, M, Lamy, T, Sanz, M, Kyrcz-Krzemien, S, Orchard, K, Hunter, A, Sandstedt, A, Fegueux, N, Bandini, G, Robinson, S, Craddock, C, Crawley, C, Griskevicius, L, Bloor, A, Reman, O, Hilgendorf, I, Cannell, P, Ciceri, F, Kalhs, P, Sica, S, Greinix, H, Scime, R, Selleslag, D, Kruger, W, Huynh, A, Einsele, H, Bittenbring, J, Olivieri, A, Hermine, O, Gedde-Dahl, T, Zsiros, J, Guyotat, D, Cordonnier, C, Campos, A, Casini, M, Martinelli, G, Muller, L, Van Imhoff, G, Neubauer, A, Lioure, B, Hamladji, R, Noens, L, Theobald, M, Salvi, F, Ram, R, Poire, X, Or, R, Chalandon, Y, Solano, C, Wilson, K, Santasusana, J, Karakasis, D, Schafer-Eckart, K, Wahlin, A, Mohty, M, Velardi, A, Bron, D, Alegre, A, Cairoli, R, Marotta, G, Lange, A, Narni, F, Fauser, A, Rambaldi, A, Guillerm, G, Heras, I, Snowden, J, Wiktor-Jedrzejczak, W, Schanz, U, Cahn, J, Abecasis, M, Kobbe, G, Salim, R, Junghanss, C, Segel, E, Clement, L, Zak, P, Metzner, B, Espigado, I, Tilly, H, Schroyens, W, Favre, C, Russo, D, Gastl, G, Bay, J, Alessandrino, E, Majolino, I, Bosi, A, Zuckerman, T, Aljurf, M, Thomson, J, Pioltelli, P, Anagnostopoulos, A, Schouten, H, Tholouli, E, Gurman, G, Vural, F, Zver, S, Muniz, S, Afanasyev, B, Pohlreich, D, Hellmann, A, Rosler, W, Martin, S, Apperley, J, Finnegan, D, Renaud, M, Nemet, D, Culligan, D, Castagna, L, Cascavilla, N, Koh, M, Chacon, M, Ozdogu, H, Spencer, A, Llamas, C, Grasso, M, Lopez, S, Benedetti, F, Deeren, D, De Revel, T, Musso, M, Halaburda, K, Sureda, A, Angelucci, E, Diez-Martin, J, Hunter, H, Koc, Y, Bordessoule, D, Fouillard, L, Di Bartolomeo, P, Mazza, P, Novitzky, N, Peschel, C, Lopez, J, Cascon, M, Romeril, K, Schots, R, Brussel, H, Koistinen, P, Arcese, W, Aktan, M, Rodeghiero, F, Butler, A, Pizzuti, M, Melpignano, A, Carella, A, Valcarcel, D, De Toledo Codina, J, Galieni, P, Bader, P, Hahn, Cavanna, L, Sucak, G, Broom, A, Garcia, P, Nicolas-Virelizier, E, Rizzoli, V, Witz, F, Collin, M, Ringhoffer, M, Kansu, E, Martin, H, Moraleda, J, Pranger, D, Greil, R, Bazarbachi, A, Ozturk, M, Fagioli, F, Jantunen, E, Yeshurun, M, Altuntas, F, Bassan, R, Rohrlich, P, Jimenez, S, Glaisner, S, Vinante, O, Clausen, J, Lopez-Jimenez, J, Theunissen, K, Specchia, G, Pavone, V, Krauter, J, Edwards, D, Rifon, J, Everaus, H, Da Prada, G, Wattad, M, Milone, G, Walewski, J, Thieblemont, C, Nasa, G, Duchosal, M, Ferrara, F, Devidas, A, Delmer, A, Degos, L, Van Gelder M., De Wreede L. C., Bornhauser M., Niederwieser D., Karas M., Anderson N. S., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen J. J., Yakoub-Agha I., Russell N. H., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., Van Biezen A., Henseler A., Schonland S., Kroger N., Schetelig J., Ehninger G., Jindra P., Sengeloev H., Russell N., Ispizua A. U., Arnold R., Veelken J. H., Mufti G., Milpied N., Benedetto B., Schaap M., Leblond V., Nikolousis M., Hallek M., Passweg J., Ljungman P., Masszi T., Stelljes M., Browne P., Glass B., Espiga C. R., Bourhis J. H., Roussy G., Gribben J., Foa R., Sierra J., Mayer J., Thomson K., Meijer E., Blau W., Holler E., Bacigalupo A., Guilhot F., Carlson K., Zachee P., Ifrah N., Marin J. R. C., Socie G., McQuaker G., Cortelezzi A., Lenhoff S., Tischer J., Irrera G., Fanin R., Beguin Y., Nagler A., Mackinnon S., Itala-Remes M., Deconinck E., Wulf G., Corradini P., Gilleece M., Wing B., Peniket A., Ganser A., Stuhler G., Faber E., Komarnicki M., Kanz L., Brune M., Lamy T., Sanz M., Kyrcz-Krzemien S., Orchard K., Hunter A., Sandstedt A., Fegueux N., Bandini G., Robinson S., Craddock C., Crawley C., Griskevicius L., Bloor A., Reman O., Hilgendorf I., Cannell P., Ciceri F., Kalhs P., Sica S., Greinix H., Scime R., Selleslag D., Kruger W., Huynh A., Einsele H., Bittenbring J., Olivieri A., Hermine O., Gedde-Dahl T., Zsiros J., Guyotat D., Cordonnier C., Campos A., Casini M., Martinelli G., Muller L. P., Van Imhoff G., Neubauer A., Lioure B., Hamladji R. -M., Noens L., Theobald M., Salvi F., Ram R., Poire X., Or R., Chalandon Y., Solano C., Wilson K., Santasusana J. M. R., Karakasis D., Schafer-Eckart K., Wahlin A., Mohty M., Velardi A., Bron D., Alegre A., Cairoli R., Marotta G., Lange A., Narni F., Fauser A., Rambaldi A., Guillerm G., Heras I., Snowden J., Wiktor-Jedrzejczak W., Schanz U., Cahn J. Y., Abecasis M., Kobbe G., Salim R., Junghanss C., Segel E. K., Clement L., Zak P., Metzner B., Espigado I., Tilly H., Schroyens W., Favre C., Russo D., Gastl G., Bay J. -O., Alessandrino E. P., Majolino I., Bosi A., Zuckerman T., Aljurf M., Thomson J., Pioltelli P., Anagnostopoulos A., Schouten H., Tholouli E., Gurman G., Vural F., Zver S., Muniz S. G., Afanasyev B., Pohlreich D., Hellmann A., Rosler W., Martin S., Apperley J., Finnegan D., Renaud M., Nemet D., Culligan D., Castagna L., Cascavilla N., Koh M., Chacon M. J., Ozdogu H., Spencer A., Llamas C. V., Grasso M., Lopez S. G., Benedetti F., Deeren D., De Revel T., Musso M., Halaburda K., Sureda A., Angelucci E., Diez-Martin J. L., Hunter H., Koc Y., Bordessoule D., Fouillard L., Di Bartolomeo P., Mazza P., Novitzky N., Peschel C., Lopez J. L. B., Cascon M. J. P., Romeril K. R., Schots R., Brussel H., Koistinen P., Arcese W., Aktan M., Rodeghiero F., Butler A., Pizzuti M., Melpignano A., Carella A. M., Valcarcel D., De Toledo Codina J. S., Galieni P., Bader P., Cavanna L., Sucak G., Broom A. J. M., Garcia P. G., Nicolas-Virelizier E., Rizzoli V., Witz F., Collin M., Ringhoffer M., Kansu E., Martin H., Moraleda J., Pranger D., Greil R., Bazarbachi A., Ozturk M., Fagioli F., Jantunen E., Yeshurun M., Altuntas F., Bassan R., Rohrlich P. -S., Jimenez S., Glaisner S., Vinante O., Clausen J., Lopez-Jimenez J., Theunissen K., Specchia G., Pavone V., Krauter J., Edwards D., Rifon J., Everaus H., Da Prada G. A., Wattad M., Milone G., Walewski J., Thieblemont C., Nasa G. L., Duchosal M., Ferrara F., Devidas A., Delmer A., and Degos L.

Abstract

Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.

Published
2017

18. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Author

Soussain, C., primary, Choquet, S., additional, Blonski, M., additional, Leclercq, D., additional, Houillier, C., additional, Rezai, K., additional, Bijou, F., additional, Houot, R., additional, Boyle, E., additional, Gressin, R., additional, Nicolas-Virelizier, E., additional, Barrie, M., additional, Moluçon-Chabrot, C., additional, Lelez, M.L., additional, Clavert, A., additional, Coisy, S., additional, Leruez, S., additional, Touitou, V., additional, Cassoux, N., additional, Daniau, M., additional, Ertault de la Bretonnière, M., additional, El Yamani, A., additional, Ghesquières, H., additional, and Hoang-Xuan, K., additional

Published
2019
Full Text
View/download PDF

19. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Bento, L, Boumendil, A, Finel, H, Le Gouill, S, Amorim, S, Monjanel, H, Bouabdallah, R, Bay, J O, Nicolas-Virelizier, E, McQuaker, G, Rossi, G, Johnson, R, Huynh, A, Ceballos, P, Rambaldi, A, Bachy, E, Malladi, R, Orchard, K, Pohlreich, D, Tilly, H, Bonifazi, F, Poire, Xavier, Guilhot, F, Haenel, A, Crawley, C, Metzner, B, Gribben, J, Russell, N H, Damaj, G, Thomson, K, Dreger, P, Montoto, S, The Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT), UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Bento, L, Boumendil, A, Finel, H, Le Gouill, S, Amorim, S, Monjanel, H, Bouabdallah, R, Bay, J O, Nicolas-Virelizier, E, McQuaker, G, Rossi, G, Johnson, R, Huynh, A, Ceballos, P, Rambaldi, A, Bachy, E, Malladi, R, Orchard, K, Pohlreich, D, Tilly, H, Bonifazi, F, Poire, Xavier, Guilhot, F, Haenel, A, Crawley, C, Metzner, B, Gribben, J, Russell, N H, Damaj, G, Thomson, K, Dreger, P, Montoto, S, and The Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Abstract

Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out the existence a particular subset of patients who could benefit from Z-BEAM conditioning that cannot be identified in our series, and this should be tested in a randomized trial.

Published
2017

21. ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS

Author

Fossard, G., primary, Broussais, F., additional, Coelho, I., additional, Bailly, S., additional, Nicolas-Virelizier, E., additional, Toussaint, E., additional, Lancesseur, C., additional, Lebras, F., additional, Willems, E., additional, Tchernonog, E., additional, Delarue, R., additional, Gressin, R., additional, Chauchet, A., additional, Gyan, E., additional, Cartron, G., additional, Bonnet, C., additional, Haioun, C., additional, Damaj, G., additional, Gaulard, P., additional, Fornecker, L., additional, Ghesquieres, H., additional, Tournilhac, O., additional, Gomes Da Silva, M., additional, Bouabdallah, R., additional, Salles, G., additional, and Bachy, E., additional

Published
2017
Full Text
View/download PDF

22. CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS

Author

Sarkozy, C., primary, Link, B., additional, Ghesquieres, H., additional, Maurer, M., additional, Nicolas-Virelizier, E., additional, Thompson, C., additional, Traverse-Glehen, A., additional, Feldman, A., additional, Allmer, C., additional, Slager, S., additional, Ansell, S., additional, Habermann, T., additional, Bachy, E., additional, Cerhan, J., additional, and Salles, G., additional

Published
2017
Full Text
View/download PDF

23. TUMOR GENOMIC COPY NUMBER ABNORMALITIES ANALYZED BY HIGH RESOLUTION SNP ARRAY IMPACT OUTCOME OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS ON 68 PATIENTS

Author

Ghesquieres, H., primary, Tesson, B., additional, Courtois-Cox, S., additional, Boyault, S., additional, Nicolas-Virelizier, E., additional, Carrere, M., additional, Traverse-Glehen, A., additional, Perrin, C., additional, Chassagne-Clement, C., additional, Jouanneau, E., additional, Salles, G., additional, Honnorat, J., additional, Blay, J., additional, and Meyronet, D., additional

Published
2017
Full Text
View/download PDF

24. THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA

Author

Ghesquieres, H., primary, Tilly, H., additional, Sonet, A., additional, Dupuis, J., additional, Nicolas-Virelizier, E., additional, Andre, M., additional, Trullemans, F., additional, Eisenmann, J., additional, Delarue, R., additional, Fleck, E., additional, Morschhauser, F., additional, and Blay, J., additional

Published
2017
Full Text
View/download PDF

25. MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE

Author

Pott, C., primary, Belada, D., additional, Danesi, N., additional, Fingerle-Rowson, G.R., additional, Gribben, J., additional, Harbron, C.G., additional, Hoster, E., additional, Kahl, B.S., additional, Kehden, B., additional, Mundt, K.E., additional, Nicolas-Virelizier, E., additional, Sehn, L.H., additional, and Cheson, B.D., additional

Published
2017
Full Text
View/download PDF

26. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE I LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.

Author

Soussain, C., primary, Choquet, S., additional, Houillier, C., additional, Bijou, F., additional, Houot, R., additional, Boyle, E., additional, Gressin, R., additional, Nicolas-Virelizier, E., additional, Barrie, M., additional, Moluçon-Chabrot, C., additional, Lelez, M., additional, Clavert, A., additional, Coisy, S., additional, de la Bretonnière, M. Ertault, additional, El Yamani, A., additional, Touitou, V., additional, Cassoux, N., additional, Boussetta, S., additional, Broussais, F., additional, Gelas-Dore, B., additional, Barzic, N., additional, Ghesquières, H., additional, and Hoang-Xuan, K., additional

Published
2017
Full Text
View/download PDF

27. A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA

Author

Morschhauser, F., primary, Le Gouill, S., additional, Feugier, P., additional, Van Den Neste, E., additional, Nicolas-Virelizier, E., additional, Bijou, F., additional, Salles, G.A., additional, Tilly, H., additional, Van Eygen, K., additional, Van Hoof, A., additional, Bonnet, C., additional, Haioun, C., additional, Bouabdallah, R., additional, Fabiani, B., additional, Xerri, L., additional, Cartron, G., additional, and Houot, R., additional

Published
2017
Full Text
View/download PDF

28. Guillain-Barre Syndrome Associated with Rapid Immune Reconstitution Following a Tandem Autologous Hematopoietic Stem Cell Transplantation. Study of a Case and Review of the Literature

Author

P.-F. Wey, C. Faulcon, H. Ghesquières, Petitjean F, A Drouet, P. Biron, L. Guilloton, and Nicolas Virelizier E

Subjects
Pediatrics, medicine.medical_specialty, Chemotherapy, Guillain-Barre syndrome, business.industry, medicine.medical_treatment, Context (language use), Hematopoietic stem cell transplantation, Disease, medicine.disease, Surgery, Immune system, immune system diseases, hemic and lymphatic diseases, medicine, Paralysis, medicine.symptom, Complication, business
Abstract

Introduction: Guillain-Barre syndrome (GBS) is a frequent cause of neuromuscular paralysis and usually occurs after an immunoallergic reaction, most often after respiratory or gastrointestinal infection. However, rare cases of Guillain-Barre syndrome are described, associated with hematopoietic stem cell transplantation. Observation: Patient n° 20452690. The authors report the case of 21 years old man, treated for Hodgkin lymphoma with a recurrence at 18 months, who enjoyed second autologous hematopoietic stem cell transplantation after conditioning chemotherapy, then developed a Guillain-Barre syndrome. Plasma exchanges were made before a neurological worsening. Thereafter, five cycles of intravenous immunoglobulin were performed monthly. Unfortunately this development was hampered by mechanical respiratory complication that led to the death of the patient, the 237th day of evolution. The final diagnosis of Guillain-Barre syndrome, occurred in a context of post-transplant immune reconstitution in a patient treated for Hodgkin lymphoma was retained. Discussion: GBS is a rare complication of hematopoietic stem cell transplantation. After literature review, we collected 33 cases related to this disease, 10 occurred after autograft. Etiopathogenic mechanisms remain obscure. Despite the use of immunomodulatory treatment, the prognosis is often severe and dark. Conclusion: GBS is possible after autologous hematopoietic stem cell transplantation indicated for the treatment of Hodgkin lymphoma. The initial clinical severity, despite safeguards and use of immunomodulatory therapy, will cause often deleterious and poor outcome. To our knowledge, this well documented observation is the first case indicated for Hodgkin lymphoma.

Published
2015
Full Text
View/download PDF

31. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

Author

Robinson, S P, primary, Boumendil, A, additional, Finel, H, additional, Blaise, D, additional, Poiré, X, additional, Nicolas-Virelizier, E, additional, Or, R, additional, Malladi, R, additional, Corby, A, additional, Fornecker, L, additional, Caballero, D, additional, Pohlreich, D, additional, Nagler, A, additional, Thieblemont, C, additional, Finke, J, additional, Bachy, E, additional, Vincent, L, additional, Schroyens, W, additional, Schouten, H, additional, and Dreger, P, additional

Published
2015
Full Text
View/download PDF

32. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study

Author

Lazarovici, J., primary, Dartigues, P., additional, Brice, P., additional, Oberic, L., additional, Gaillard, I., additional, Hunault-Berger, M., additional, Broussais-Guillaumot, F., additional, Gyan, E., additional, Bologna, S., additional, Nicolas-Virelizier, E., additional, Touati, M., additional, Casasnovas, O., additional, Delarue, R., additional, Orsini-Piocelle, F., additional, Stamatoullas, A., additional, Gabarre, J., additional, Fornecker, L.-M., additional, Gastinne, T., additional, Peyrade, F., additional, Roland, V., additional, Bachy, E., additional, Andre, M., additional, Mounier, N., additional, and Ferme, C., additional

Published
2015
Full Text
View/download PDF

33. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Author

Kastritis, E., primary, Leleu, X., additional, Arnulf, B., additional, Zamagni, E., additional, Cibeira, M.T., additional, Kwok, F., additional, Mollee, P., additional, Hájek, R., additional, Moreau, P., additional, Jaccard, A., additional, Schönland, S., additional, Filshie, R., additional, Nicolas-Virelizier, E., additional, Augustson, B., additional, Mateos, M.-V., additional, Wechalekar, A., additional, Hachulla, E., additional, Milani, P., additional, Dimopoulos, M.A., additional, Fermand, J.-P., additional, Foli, A., additional, Gavriatopoulou, M., additional, Palumbo, A., additional, Sonneveld, P., additional, Johnsen, H.E., additional, Merlini, G., additional, and Palladini, G., additional

Published
2015
Full Text
View/download PDF

35. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Mounier, N., Brice, P., Bologna, S., Briere, J., Gaillard, I., Heczko, M., Gabarre, J., Casasnovas, O., Jaubert, J., Colin, P., Delmer, A., Devidas, A., Bachy, E., Nicolas-Virelizier, E., Aoudjhane, A., Humbrecht, C., André, M., Carde, P., Divine, M., Fenaux, P., Coiffier, B., Reman, O., Aoudjhane, M., Blaise, A.M., Bordessoule, D., Bosly, André, Morschhauser, F., Caillot, D., Gonzalez, H., Lederlin, P., Bouabdallah, R., van Hoof, A., Boulat, O., Bauduer, F., Tournilhac, O., Decaudin, D., Sebban, C., Janvier, M., Kentos, A., Voillat, L., Fabbro, M., Eisenmann, J.C., Martin, C., Christian, B., Ferrant, Augustin, Salanoubat, C., Varet, B., Bouabdallah, K., de Prijck, B., Levaltier, X., Castaigne, S., Audhuy, B., Frenkiel, N., Rose, C., Fitoussi, O., Orfeuvre, H., Pignon, J.M., UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Mounier, N., Brice, P., Bologna, S., Briere, J., Gaillard, I., Heczko, M., Gabarre, J., Casasnovas, O., Jaubert, J., Colin, P., Delmer, A., Devidas, A., Bachy, E., Nicolas-Virelizier, E., Aoudjhane, A., Humbrecht, C., André, M., Carde, P., Divine, M., Fenaux, P., Coiffier, B., Reman, O., Aoudjhane, M., Blaise, A.M., Bordessoule, D., Bosly, André, Morschhauser, F., Caillot, D., Gonzalez, H., Lederlin, P., Bouabdallah, R., van Hoof, A., Boulat, O., Bauduer, F., Tournilhac, O., Decaudin, D., Sebban, C., Janvier, M., Kentos, A., Voillat, L., Fabbro, M., Eisenmann, J.C., Martin, C., Christian, B., Ferrant, Augustin, Salanoubat, C., Varet, B., Bouabdallah, K., de Prijck, B., Levaltier, X., Castaigne, S., Audhuy, B., Frenkiel, N., Rose, C., Fitoussi, O., Orfeuvre, H., and Pignon, J.M.

Abstract

Background: Treatment with escalated BEACOPP achieved a superior time to treatment failure over ABVD in patients with disseminated Hodgkin lymphoma. However, recent clinical trials have failed to confirm BEACOPP overall survival (OS) superiority over ABVD. In addition, the gain in low-risk patients is still a matter of debate. Patients and methods: We randomly compared ABVD (8 cycles) with BEACOPP (escalated 4 cycles ≥baseline 4 cycles) in low-risk patients with an International Prognostic Score (IPS) of 0-2. The primary end point was event-free survival (EFS). This parallel group, open-label phase 3 trial was registered under #RECF0219 at French National Cancer Institute. Results: One hundred and fifty patients were randomized in this trial (ABVD 80, BEACOPP 70): 28 years was the median age, 50% were male and IPS was 0-1 for 64%. Complete remission rate was 85% for ABVD and 90% for BEACOPP. Progression or relapses were more frequent in the ABVD patients than in the BEACOPP patients (17 versus 5 patients). With a median follow-up period of 5.5 years, seven patients died: six in the ABVD arm and one in the BEACOPP arm (HL 3 and 0, 2nd cancer 2 and 1, accident 1 and 0). The EFS at 5 years was estimated at 62% for ABVD versus 77%, for BEACOPP [hazards ratio (HR) = 0.6, P = 0.07]. The progression-free survival (PFS) at 5 years was 75% versus 93% (HR = 0.3, P=0.007). The OS at 5 years was 92% versus 99% (HR = 0.18, P = 0.06). Conclusion: Fewer progressions/relapses were observed with BEACOPP, demonstrating the high efficacy of the more intensive regimen, even in low-risk patients. However, additional considerations, balancing treatment-related toxicity and late morbidity due to salvage may help with decision-making with regard to treatment with ABVD or BEACOPP. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Published
2014

36. Impact of Response to Induction Chemotherapy in Patients with Germ Cell Tumors (Gct) Receiving Salvage High-Dose Chemotherapy (Hdct): a Study of the Ebmt Solid Tumors Working Party (Stwp)

Author

Necchi, A., primary, Miceli, R., additional, Berger, L.A., additional, Schumacher, K., additional, Bourhis, J.H., additional, Laszlo, D., additional, Nicolas-Virelizier, E., additional, Arpaci, F., additional, Secondino, S., additional, Dreger, P., additional, Kruger, W., additional, Ringhoffer, M., additional, Unal, A., additional, Nagler, A., additional, Campos, A., additional, Wahlin, A., additional, Donnini, I., additional, Badoglio, M., additional, Pedrazzoli, P., additional, and Lanza, F., additional

Published
2014
Full Text
View/download PDF

37. MEDICAL RADIATION THERAPIES

Author

Ahmed, I., primary, Biswas, A., additional, Krishnamurthy, S., additional, Julka, P., additional, Rath, G., additional, Back, M., additional, Huang, D., additional, Gzell, C., additional, Chen, J., additional, Kastelan, M., additional, Gaur, P., additional, Wheeler, H., additional, Badiyan, S. N., additional, Robinson, C. G., additional, Simpson, J. R., additional, Tran, D. D., additional, Rich, K. M., additional, Dowling, J. L., additional, Chicoine, M. R., additional, Leuthardt, E. C., additional, Kim, A. H., additional, Huang, J., additional, Michaelsen, S. R., additional, Christensen, I. J., additional, Grunnet, K., additional, Stockhausen, M.-T., additional, Broholm, H., additional, Kosteljanetz, M., additional, Poulsen, H. S., additional, Tieu, M., additional, Lovblom, E., additional, Macnamara, M., additional, Mason, W., additional, Rodin, D., additional, Tai, E., additional, Ubhi, K., additional, Laperriere, N., additional, Millar, B.-A., additional, Menard, C., additional, Perkins, B., additional, Chung, C., additional, Clarke, J., additional, Molinaro, A., additional, Phillips, J., additional, Butowski, N., additional, Chang, S., additional, Perry, A., additional, Costello, J., additional, DeSilva, A., additional, Rabbitt, J., additional, Prados, M., additional, Cohen, A. L., additional, Anker, C., additional, Shrieve, D., additional, Hall, B., additional, Salzman, K., additional, Jensen, R., additional, Colman, H., additional, Farber, O., additional, Weinberg, U., additional, Palti, Y., additional, Fisher, B., additional, Chen, H., additional, Macdonald, D., additional, Lesser, G., additional, Coons, S., additional, Brachman, D., additional, Ryu, S., additional, Werner-Wasik, M., additional, Bahary, J.-P., additional, Chakravarti, A., additional, Mehta, M., additional, Gupta, T., additional, Nair, V., additional, Epari, S., additional, Godasastri, J., additional, Moiyadi, A., additional, Shetty, P., additional, Juvekar, S., additional, Jalali, R., additional, Herrlinger, U., additional, Schafer, N., additional, Steinbach, J., additional, Weyerbrock, A., additional, Hau, P., additional, Goldbrunner, R., additional, Kohnen, R., additional, Urbach, H., additional, Stummer, W., additional, Glas, M., additional, Houillier, C., additional, Ghesquieres, H., additional, Chabrot, C., additional, Soussain, C., additional, Ahle, G., additional, Choquet, S., additional, Faurie, P., additional, Bay, J.-O., additional, Vargaftig, J., additional, Gaultier, C., additional, Nicolas-Virelizier, E., additional, Hoang-Xuan, K., additional, Iskanderani, O., additional, Izar, F., additional, Benouaich-Amiel, A., additional, Filleron, T., additional, Moyal, E., additional, Iweha, C., additional, Jain, S., additional, Melian, E., additional, Sethi, A., additional, Albain, K., additional, Shafer, D., additional, Emami, B., additional, Kong, X.-T., additional, Green, S., additional, Filka, E., additional, Green, R., additional, Yong, W., additional, Nghiemphu, P., additional, Cloughesy, T., additional, Lai, A., additional, Mallick, S., additional, Roy, S., additional, Purkait, S., additional, Gupta, S., additional, Julka, P. K., additional, Rath, G. K., additional, Marosi, C., additional, Thaler, J., additional, Ay, C., additional, Kaider, A., additional, Reitter, E.-M., additional, Haselbock, J., additional, Preusser, M., additional, Flechl, B., additional, Zielinski, C., additional, Pabinger, I., additional, Miyatake, S.-I., additional, Furuse, M., additional, Miyata, T., additional, Yoritsune, E., additional, Kawabata, S., additional, Kuroiwa, T., additional, Muragaki, Y., additional, Maruyama, T., additional, Iseki, H., additional, Akimoto, J., additional, Ikuta, S., additional, Nitta, M., additional, Maebayashi, K., additional, Saito, T., additional, Okada, Y., additional, Kaneko, S., additional, Matsumura, A., additional, Karasawa, K., additional, Nakazato, Y., additional, Kayama, T., additional, Nabors, L. B., additional, Fink, K. L., additional, Mikkelsen, T., additional, Grujicic, D., additional, Tarnawski, R., additional, Nam, D.-H., additional, Mazurkiewicz, M., additional, Salacz, M., additional, Ashby, L., additional, Thurzo, L., additional, Zagonel, V., additional, Depenni, R., additional, Perry, J. R., additional, Henslee-Downey, J., additional, Picard, M., additional, Reardon, D. A., additional, Nambudiri, N., additional, Nayak, L., additional, LaFrankie, D., additional, Wen, P., additional, Ney, D., additional, Carlson, J., additional, Damek, D., additional, Blatchford, P., additional, Gaspar, L., additional, Kavanagh, B., additional, Waziri, A., additional, Lillehei, K., additional, Reddy, K., additional, Chen, C., additional, Rashed, I., additional, Barton, K., additional, Anderson, D., additional, Prabhu, V., additional, Rusch, R., additional, Belongia, M., additional, Maheshwari, M., additional, Firat, S., additional, Schiff, D., additional, Desjardins, A., additional, Glantz, M., additional, Chamberlain, M., additional, Shapiro, W., additional, Gopal, S., additional, Judy, K., additional, Patel, S., additional, Mahapatra, A., additional, Shan, J., additional, Gupta, D., additional, Shih, K., additional, Bacha, J. A., additional, Brown, D., additional, Garner, W. J., additional, Steino, A., additional, Schwart, R., additional, Kanekal, S., additional, Li, M., additional, Lopez, L., additional, Burris, H. A., additional, Soderberg-Naucler, C., additional, Rahbar, A., additional, Stragliotto, G., additional, Song, A. J., additional, Kumar, A. M. S., additional, Murphy, E. S., additional, Tekautz, T., additional, Suh, J. H., additional, Recinos, V., additional, Chao, S. T., additional, Spoor, J., additional, Korami, K., additional, Kloezeman, J., additional, Balvers, R., additional, Dirven, C., additional, Lamfers, M., additional, Leenstra, S., additional, Sumrall, A., additional, Haggstrom, D., additional, Crimaldi, A., additional, Symanowski, J., additional, Giglio, P., additional, Asher, A., additional, Burri, S., additional, Sunkersett, G., additional, Khatib, Z., additional, Prajapati, C. M., additional, Magalona, E. E., additional, Mariano, M., additional, Sih, I. M., additional, Torcuator, R., additional, Taal, W., additional, Oosterkamp, H., additional, Walenkamp, A., additional, Beerenpoot, L., additional, Hanse, M., additional, Buter, J., additional, Honkoop, A., additional, Boerman, D., additional, de Vos, F., additional, Jansen, R., additional, van der Berkmortel, F., additional, Brandsma, D., additional, Enting, R., additional, Kros, J., additional, Bromberg, J., additional, van Heuvel, I., additional, Smits, M., additional, van der Holt, R., additional, Vernhout, R., additional, van den Bent, M., additional, Wick, W., additional, Suarez, C., additional, Rodon, J., additional, Forsyth, P., additional, Gueorguieva, I., additional, Cleverly, A., additional, Burkholder, T., additional, Desaiah, D., additional, Lahn, M., additional, Zach, L., additional, Guez, D., additional, Last, D., additional, Daniels, D., additional, Nissim, O., additional, Grober, Y., additional, Hoffmann, C., additional, Nass, D., additional, Talianski, A., additional, Spiegelmann, R., additional, Cohen, Z., additional, and Mardor, Y., additional

Published
2013
Full Text
View/download PDF

38. 860P - Impact of Response to Induction Chemotherapy in Patients with Germ Cell Tumors (Gct) Receiving Salvage High-Dose Chemotherapy (Hdct): a Study of the Ebmt Solid Tumors Working Party (Stwp)

Author

Necchi, A., Miceli, R., Berger, L.A., Schumacher, K., Bourhis, J.H., Laszlo, D., Nicolas-Virelizier, E., Arpaci, F., Secondino, S., Dreger, P., Kruger, W., Ringhoffer, M., Unal, A., Nagler, A., Campos, A., Wahlin, A., Donnini, I., Badoglio, M., Pedrazzoli, P., and Lanza, F.

Published
2014
Full Text
View/download PDF

39. Radioimmunotherapy and BEAM chemotherapy versus BEAM as the conditioning regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective matched-control study of the LWP-EBMT

Author

Bento, L., Boumendil, A., Finel, H., Chevallier, P., Amorim, S., Monjanel, H., Blaise, D., Bay, J-O, Nicolas-Virelizier, E., Mcquaker, G., Rossi, G., Johnson, R., Huynh, A., Fegueux, N., Rambaldi, A., Gilles Salles, Craddock, C., Orchard, K., Pohlreich, D., Tilly, H., Bandini, G., Poire, X., Guilhot, F., Haenel, A., Crawley, C., Metzner, B., Gribben, J., Russell, N. H., Damaj, G., Thomson, K., Dreger, P., and Montoto, S.

41. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.

Author

Soussain, C., Choquet, S., Houillier, C., Bijou, F., Houot, R., Boyle, E., Gressin, R., Nicolas ‐ Virelizier, E., Barrie, M., Moluçon ‐ Chabrot, C., Lelez, M., Clavert, A., Coisy, S., Bretonnière, M. Ertault, El Yamani, A., Touitou, V., Cassoux, N., Boussetta, S., Broussais, F., and Gelas ‐ Dore, B.

Published
2017
Full Text
View/download PDF

42. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

Author

Andrea Foli, Pieter Sonneveld, Xavier Leleu, Giovanni Palladini, Efstathios Kastritis, Eric Hachulla, Arnaud Jaccard, Emmanuelle Nicolas-Virelizier, Bradley Augustson, Peter Mollee, Fiona Kwok, Jean Paul Fermand, Maria-Victoria Mateos, María Teresa Cibeira, Giampaolo Merlini, Maria Gavriatopoulou, Hans Erik Johnsen, Paolo Milani, Antonio Palumbo, Roman Hájek, Philippe Moreau, Robin Filshie, Catherine Klersy, Meletios A. Dimopoulos, Ashutosh D. Wechalekar, Stefan Schönland, Elena Zamagni, Bertrand Arnulf, Hematology, Kastritis E., Leleu X., Arnulf B., Zamagni E., Cibeira M.T., Kwok F., Mollee P., Hajek R., Moreau P., Jaccard A., Schonland S.O., Filshie R., Nicolas-Virelizier E., Augustson B., Mateos M.-V., Wechalekar A., Hachulla E., Milani P., Dimopoulos M.A., Fermand J.-P., Foli A., Gavriatopoulou M., Klersy C., Palumbo A., Sonneveld P., Erik Johnsen H., Merlini G., and Palladini G.

Subjects
Melphalan, Male, Cancer Research, medicine.medical_specialty, Administration, Oral, Gastroenterology, Dexamethasone, Bortezomib, Bortezomib, melphalan, dexamethasone, light-chain amyloidosis, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, AL amyloidosis, Humans, Immunoglobulin Light-chain Amyloidosis, Progression-free survival, Aged, Cytopenia, business.industry, Amyloidosis, Hazard ratio, Middle Aged, medicine.disease, Hematologic Response, Progression-Free Survival, Oncology, Female, business, medicine.drug
Abstract

PURPOSE Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex). METHODS This was a phase III, multicenter, randomized, open-label trial. Patients were stratified according to cardiac stage. Patients with advanced cardiac stage (stage IIIb) amyloidosis were not eligible. The primary end point was hematologic response rate at 3 months. This trial is registered with ClinicalTrials.gov identifier NCT01277016 . RESULTS A total of 109 patients, 53 in the BMDex and 56 in the MDex group, received ≥ 1 dose of therapy (from January 2011 to February 2016). Hematologic response rate at 3 months was higher in the BMDex arm (79% v 52%; P = .002). Higher rates of very good partial or complete response rates (64% v 39%; hazard ratio [HR], 2.47; 95% CI, 1.30 to 4.71) and improved overall survival, with a 2-fold decrease in mortality rate (HR, 0.50; 95% CI, 0.27 to 0.90), were observed in the BMDex arm. Grade 3 and 4 adverse events (the most common being cytopenia, peripheral neuropathy, and heart failure) were more common in the BMDex arm, occurring in 20% versus 10% of cycles performed. CONCLUSION BMDex improved hematologic response rate and overall survival. To our knowledge, this is the first time a controlled study has demonstrated a survival advantage in AL amyloidosis. BMDex should be considered a new standard of care for AL amyloidosis.

Published
2020
Full Text
View/download PDF

43. Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.

Author

Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, Alcantara M, Molina L, Ceraulo A, Poirée M, Galtier J, Diop N, Delette C, Segot A, Dubois S, Waultier A, Bernard S, Noël R, Guidez S, Kohn M, Bailly S, Moatti H, Touati M, Renaud L, Kanoun S, Cottereau AS, Kirova Y, Peignaux K, Dourthe ME, Simonin M, Leblanc T, Quéro L, Krzisch D, Duléry R, Grenier A, Gastinne T, Casasnovas O, Gallamini A, André M, Morschhauser F, Deau B, Fornecker LM, and Ghesquières H

Abstract

Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL., Competing Interests: Declaration of Competing Interest CR has received a research grant from Roche and personal fees and non-financial support from Janssen, Roche, Takeda, and Abbvie. ROC has received a research grant from Gilead and Takeda and personal fees and non-financial support from Janssen, Roche, Takeda, Merck/BMS, Abbvie, and Amgen. The other authors declare no competing interests. MA performed scientific and medical consul/ng for Novar/s, Janssen, Kite/Gilead and MSD and received research grants from Mnemo Therapeutics. R.D. reports honoraria from Novar/s and Takeda; and support for attending meetings and/or travel from Sanofi and Kite Pharma / Gilead. GM reports honoraria from Takeda, Bristol Myers Squibb, Gilead Kite, and Abbvie. All remaining authors have declared no conflicts of interest, (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2024
Full Text
View/download PDF

44. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.

Author

Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Waultier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, and Casasnovas O

Subjects
Humans, Aged, Middle Aged, Aged, 80 and over, Vinblastine adverse effects, Prednisone adverse effects, Bendamustine Hydrochloride adverse effects, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Doxorubicin adverse effects, Cyclophosphamide, Vincristine, Hodgkin Disease pathology
Abstract

Abstract: Older patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, prospective, phase 2 study, we investigated a new firstline therapy regimen comprising 6 cycles of prednisone (40 mg/m2, days 1-5), vinblastine (6 mg/m2, day 1), doxorubicin (40 mg/m2, day 1), and bendamustine (120 mg/m2, day 1) (PVAB regimen) every 21 days for patients with newly diagnosed cHL aged ≥61 years with an advanced Ann Arbor stage. A Mini Nutritional Assessment score ≥17 was the cutoff value for patients aged ≥70 years. The primary end point was the complete metabolic response (CMR) rate after 6 cycles. The median age of the 89 included patients was 68 years (range, 61-88 years), with 35 patients (39%) aged ≥70 years. Seventy-eight patients (88%) completed the 6 cycles. The toxicity rate was acceptable, with a 20% rate of related serious adverse events. CMR was achieved by 69 patients (77.5%; 95% confidence interval [CI], 67-86). After a median follow-up of 42 months, 31 patients progressed or relapsed (35%), and 24 died (27%) from HL (n = 11), toxicity during treatment (n = 4), secondary cancers (n = 6), or other causes (n = 3). The 4-year progression-free survival (PFS) and overall survival rates were 50% and 69%, respectively. Multivariate analysis showed that liver involvement (P = .001), lymphopenia (P = .001), CRP (P = .0005), and comedications (P = .003) were independently associated with PFS. The PVAB regimen yielded a high CMR rate with acceptable toxicity. Over long-term follow-up, survival end points were influenced by unrelated lymphoma events. This trial was registered at www.clinicaltrials.gov as #NCT02414568 and at EudraCT as 2014-001002-17., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

45. Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.

Author

Walczak P, Choquet S, Dantal J, Boutboul D, Suarez F, Baron M, Morel V, Cluzeau T, Touati M, Elias M, Bachy E, Nicolas-Virelizier E, Houot R, Venton G, Jacquet C, Moles-Moreau MP, Jardin F, Durot E, Balegroune N, Ecotiere L, Guieze R, Kamar N, Ysebaert L, Couzi L, Gonzalez H, Roulin L, Ou K, Caillard S, Zimmermann H, Trappe RU, and Roos-Weil D

Subjects
Humans, Retrospective Studies, Cyclophosphamide therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Burkitt Lymphoma genetics, Burkitt Lymphoma drug therapy
Published
2023
Full Text
View/download PDF

46. Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.

Author

Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E, Hayette S, Tigaud I, Plesa A, Labussiere-Wallet H, Sobh M, Michallet AS, Marie B, Nicolini FE, Guillermin Y, Gaëlle F, Lebras L, Rey P, Jauffret-Bertholon L, Laude MC, Sandrine L, and Michallet M

Subjects
Adult, Humans, Prognosis, Disease-Free Survival, Remission Induction, Hospitals, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy
Abstract

Background: t-AML occurs after a primary malignancy treatment and retains a poor prognosis., Aims: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML., Results: A total of 112 adult patients were included in this study. Fifty-Five patients received intensive chemotherapy (IC), 33 non-IC, and 24 best supportive care. At t-AML diagnosis, 42% and 44% of patients presented an unfavorable karyotype and unfavorable 2010 ELN risk profile, respectively. Among treated patients (n = 88), 43 (49%) achieved complete remission: four out of 33 (12%) and 39 out of 55 (71%) in non-IC and IC groups, respectively. With a median follow-up of 5.5 months, the median overall survival (OS) and disease-free survival (DFS) for the whole population were 9 months and 6.3 months, respectively, and for the 88 treated patients 13.5 months and 8.2 months, respectively. Univariate analysis on OS and DFS showed a significant impact of high white blood cells (WBC) and blast counts at diagnosis, unfavorable karyotype and ELN classification. Multivariate analysis showed a negative impact of WBC count at diagnosis and a positive impact of chemotherapy on OS and DFS in the whole population. It also showed a negative impact of previous auto-HCT and high WBC count on OS and DFS and of IC on OS in treated patients which disappeared when we considered only confounding variables (age, previous cancers, marrow blasts, and 2010 ELN classification). In a pair-matched analysis comparing IC treated t-AML with de novo AML, there was no difference of OS and DFS between the two populations., Conclusion: We showed, in this study that t-AML patients with unfavorable features represented almost half of the population. Best outcomes obtained in patients receiving IC must be balanced by known confounding variables and should be improved by using new innovative agents and therapeutic strategies., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

48. Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.

Author

Beldi-Ferchiou A, Jais JP, Ghesquieres H, Casasnovas RO, Tilly H, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Perrot A, Nicolas-Virelizier E, Salles G, Godard N, Zamali I, De Colella JS, Claudel A, Corront B, Oberic L, Briere J, Gaulard P, Thieblemont C, and Delfau-Larue MH

Subjects
Aged, Humans, Cell Count, Lenalidomide therapeutic use, Prognosis, Rituximab therapeutic use, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Neoplasm Recurrence, Local drug therapy
Abstract

Low baseline NK-cell counts (NKCCs) in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a poor prognosis. The REMARC phase III trial (NCT01122472) showed that lenalidomide maintenance prolonged PFS in rituximab-chemotherapy responders. We conducted a REMARC ancillary study analysing the impact of lenalidomide maintenance on the prognostic value of low NKCCs. Blood samples from 335 elderly French patients enrolled in the REMARC trial were analysed by flow cytometry to obtain NKCCs at diagnosis (n = 220), at randomization (n = 186) and/or six months after randomization (n = 184). Baseline NKCCs < 100 cells/μl were associated with shorter PFS and OS (HRs = [2.2 (1.4, 3.3), p < 0.001] and [2.8 (1.7, 4.5), p < 0.001], respectively), independently of aaIPI. In a competing risk analysis, low NKCCs at baseline were associated with a higher risk of relapse/progression (p = 0.0025), but not of death without progression (p = 0.33). Lenalidomide did not affect the prognosis value of low baseline NKCCs (p  = 0.6349). Similar results were obtained for low NKCCs at randomization. Our results demonstrate that low NKCCs at baseline and post rituximab-chemotherapy are robust prognostic factors in DLBCL and reveal that lenalidomide has no impact on this parameter. Other therapeutic strategies aiming at improving NK-cell function could improve outcomes in DLBCL., (© 2023 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

49. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Author

Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, and André M

Subjects
Humans, Adolescent, Young Adult, Adult, Middle Aged, Brentuximab Vedotin, Bleomycin, Vinblastine, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dacarbazine, Neoplasm Staging, Treatment Outcome, Hodgkin Disease diagnostic imaging, Hodgkin Disease drug therapy, Hodgkin Disease pathology
Abstract

Purpose: The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979)., Methods: BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD., Results: Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively., Conclusion: BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2023
Full Text
View/download PDF

50. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.

Author

Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, Fruchart C, Casasnovas O, Michot JM, Molina TJ, Bosly A, Joubert C, Haioun C, Nicolas-Virelizier E, Feugier P, Fitoussi O, Delarue R, and Tilly H

Subjects
Humans, Rituximab therapeutic use, Treatment Outcome, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived, Follow-Up Studies, Prednisone therapeutic use, Vincristine therapeutic use, Prospective Studies, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm Recurrence, Local drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy
Abstract

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years with an aaIPI (age-adjusted International Prognostic Index) score ≥1 (registered as NCT00144755). We implemented a prospective long-term follow-up program at the end of this trial. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Relapse patterns, PFS and OS after the first progression (PFS2 and OS2) were secondary endpoints. LNH03-6B was registered with ClinicalTrials.gov #NCT00144755. In the LNH03-6B trial, 304 and 296 patients were assigned to receive 8 cycles of R-CHOP14 or R-CHOP21, respectively. Long-term follow-up data were investigated for 256 of 384 (67%) patients still alive at the primary analysis. With a median follow-up of 10.1 years, 213 patients progressed, and 140 patients died without progression. The 10-year PFS was 40.4% (95% confidence interval, 35.9-44.9). Ten-year OS was based on 302 deaths and estimated at 50% (43-56). Of the 213 patients, 105 (49%) progressed after second-line therapy, and 77 patients died without a second progression (36%). The 1-year PFS2 and 1-year OS2 were estimated at 37.9% (95% confidence interval, 31.4-44.5) and 55.8% (95% confidence interval, 48.8-62.2), respectively. Ten years after randomization, the outcomes of patients treated for DLBCL were similar according to PFS and OS between the RCHOP-14 and R-CHOP21 groups. Progression or relapse led to poor prognosis after second-line chemotherapy in the pre CAR-T-cell era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results